FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Natural GH Secretagogue

GH Optimizationbeginner
50
Share
펩타이드

2

일 평균 mcg

414

수준

beginner

추가됨

May 16, 2026

개요

The Natural GH Secretagogue is a clean, beginner-friendly peptide stack designed to restore youthful growth hormone output through gentle, physiological stimulation of the pituitary gland. By combining Ipamorelin, a highly selective ghrelin receptor agonist, with Sermorelin, a truncated analog of natural growth hormone-releasing hormone, this protocol mimics the body own GH secretion patterns while amplifying their magnitude. Ipamorelin at 200mcg daily delivers targeted GH pulses by activating ghrelin receptors on pituitary somatotroph cells. What distinguishes Ipamorelin from other secretagogues is its remarkable selectivity: it stimulates growth hormone release without elevating cortisol, ACTH, prolactin, or aldosterone, and it does not significantly increase appetite. This clean pharmacological profile makes it the most side-effect-friendly GH peptide available. Sermorelin at 300mcg on a 5-days-on/2-days-off schedule activates the GHRH receptor, providing the primary physiological signal for GH synthesis and release. The cycling protocol preserves receptor sensitivity and prevents the downregulation that can occur with continuous GHRH exposure. The synergy between these two peptides operates through complementary receptor systems: Sermorelin primes the pituitary through the GHRH pathway while Ipamorelin amplifies the release through the ghrelin pathway. Research demonstrates that co-administration of GHRH and ghrelin-mimetic peptides produces GH output greater than either alone, often approaching supraphysiological levels from purely secretagogue-driven mechanisms. Administer both peptides before bed on an empty stomach (no food for 2-3 hours prior) to coincide with the natural nocturnal GH surge. On Sermorelin rest days (weekends), Ipamorelin alone maintains baseline GH support. This stack is ideal for beginners aged 30 and above who are noticing early signs of GH decline: reduced recovery capacity, increased body fat around the midsection, lighter sleep, and slower healing. It is also suited for those who want the benefits of optimized GH without the complexity or cost of multi-peptide advanced protocols. Users can expect improved sleep quality within the first week, enhanced recovery within 2-3 weeks, and body composition changes over 8-12 weeks. No harsh side effects are expected at these doses. Standard cycle length is 12 weeks with a 4-week break, and blood work (IGF-1, fasting glucose) is recommended at baseline and mid-cycle.

용량 프로토콜

200 mcg

1회 용량당

300 mcg

1회 용량당

목표 및 증거

증거 등급:community

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.